No results for ‘’
Gland Pharma Ltd
NSE: GLAND BSE: 543245
₹2502.90
(0.56%)
Fri, 07 Aug 2026, 11:23 am
Market Cap (in Cr)41312.5
PE Ratio40.16
Dividend0.72
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1978
- The company was incorporated as Gland Pharma Private Limited
1994
- The name of the company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders
1995
- A fresh certificate of incorporation was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company
2000
- The company set up the in-house R&D facility at Dundigal, Hyderabad
2003
- The company received USFDA approval for the manufacturing facility at Dundigal
2005
- The company launched Enoxaparin Sodium Injection (Cutenox) in India and Rest of the world markets
2007
- The company received a capital infusion of approximately 1,000 million into the Company pursuant to private equity investment aggregating to approximately 1,200 million with EILSF Co-Invest I LLC
2010
- The company launched Heparin Sodium Injection in the US
2012
- The company received the Certificate of GMP Compliance of a Manufacturer from BGV Hamburg (Germany) for its manufacturing facility at Dundigal
2014
- The company obtained USFDA approval for small volume parenteral manufacturing facility at Visakhapatnam
- The company commissioned the Pashamylaram Unit-II manufacturing facility
- The company received the Certificate of GMP Compliance of a Manufacturer from MHRA (UK) for manufacturing facility at Dundigal
- The company received a capital infusion of US$ 100 million into the Company pursuant to private equity investment aggregating to approximately US$ 200 million with KKR Floorline Investment Pte Ltd
2016
- The company obtained USFDA approval for its facilities at Jawaharlal Nehru Pharma City, Visakhapatnam
- The company obtained USFDA approval for its manufacturing facility at Pashamylaram
- The company obtained USFDA approval for its facility at the Visakhapatnam Special Economic Zone
2017
- Fosun Singapore acquired 74% stake in the company
2018
- The company received ANDA approval for Enoxaparin Sodium Injection USP for the US market
- The company received ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%, its first Ophthalmic product approval
2019
- The company filed Dexrazoxane for Injection, its first filing with the National Medical Products Administration, China, and received clinical waiver
2020
- Gland Pharma along with its partners MAIA Pharmaceuticals, Inc. and Athenex Pharmaceutical Division announce the launch of a Ready-to-Use Bivalirudin Injection in the United States of America
2021
- Gland Pharma received approval for generic Foscarnet Sodium Injection, Single-Dose Bag for Infusion
- Gland Pharma receives Tentative Approval for Sugammadex Injection
- Gland Pharma receives tentative approval for Cangrelor injection
2022
- Gland Pharma enters into put option agreement to acquire 100% of Cenexi Group
- Gland Pharma announces launch of Bortezomib for Injection in US market
2024
- The Company received approval from the United States Food and Drug Administration (US FDA) for Plerixafor Injection